CompanyDeals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

CompanyDrug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

CompanyDrug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

CompanyDrug

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

CompanyDrug

CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma

CompanyMedical Device

MicroPort NeuroScientific’s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China’s First Targeted-Release Self-Expanding System

CompanyDeals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention

Others

Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US

CompanyDrug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

CompanyDrug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Company

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations